Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Phenotypic clusters in HFpEF

5' education - July 28, 2021 - Alicia Uijl, PhD

Patient profiling in HFrEF to tailor therapy

5' education - June 21, 2001 - Pardeep Jhund, MD, PhD

No definite difference for primary endpoint but proven safety with ARNI in MI patients

5' education - May 15, 2021 - Prof. Marc Pfeffer, MD, PhD

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD

Treatment algorithms for HFpEF

10' education - May 4, 2021 - Prof. John Cleland, MD

Recommendations for treatment algorithm of HFrEF

10' education - Apr. 26, 2021 - Andrew Coats, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Two medical therapies elevated to front line in 2021 update HF ECDP

5' education - Feb. 1, 2021 - Prof. James Januzzi, MD

Clinical outcome trial with IV iron in patients with iron deficiency, stabilized after acute HF

3' education - Dec. 15, 2020 - Prof. Peter van der Meer, MD, PhD

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Introduction: Optimizing RAASi treatment through long-term potassium control

10' education - Oct. 22, 2020 - Prof. Peter van der Meer, MD

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD - Online CME

Understanding risk of hyperkalemia in heart failure

10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD - Online CME

Heart failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD - Online CME

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD

Setting a patient on the right track following hospitalization for ADHF

15' education - Sep. 14, 2020 - Alexander Cadenbach, MD and prof. Mark Petrie, MD - Online CME

Iron deficiency in patients with heart failure

10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

How to diagnose and treat amyloidosis?

10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Succes with SGLT2 inhibitor in HFrEF for all three end points

3' education - Aug. 29, 2020 - Milton Packer, MD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

How will outcomes of ARNI trials impact diagnosis and management of HF?

10' education - Aug. 26, 2020 - Prof. Mark Petrie, MD

3rd Groningen Heart failure symposium: How to implement the newest HF therapies?

10' education - Aug. 25, 2020 - Prof. Dirk Jan van Veldhuisen, MD and prof. Adriaan Voors, MD

Getting better at diagnosing HFpEF - sharing clinical practice experience

15' education - July 28, 2020 - Prof. Mark Petrie, MD and Pardeep Jhund, MD, PhD - Online CME

Improving outcomes for patients following an admission with ADHF

15' education - July 7, 2020 - Prof. Mark Petrie, MD and Klaus Witte, MD - Online CME

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD

Phenotypic clusters in HFpEF

5' education - July 28, 2021 - Alicia Uijl, PhD
Alicia Uijl presents the results of an analysis that identified five phenotypic clusters in HFpEF with differences in medication profile, morbidity and mortality.

Alicia Uijl presents the results of an analysis that identified five phenotypic clusters in HFpEF with differences in medication profile, morbidity and mortality.

T2DM-related microvascular disease associated with incident HF

Literature - July 27, 2021 - Kaze AD, et al. - J Am Heart Assoc. 2021

Microvascular disease (MVD) was associated with the development of HF in adults with T2DM, independently of traditional risk factors including CAD.

Suboptimal use of evidence-based medical therapies in patients with HFrEF and CKD

Literature - July 14, 2021 - Patel RB et al. - J Am Coll Cardiol. 2021

This study showed that prescription rates of evidence-based medical therapies are suboptimal in patients with comorbid HFrEF and CKD, even at eGFR levels where therapies are not contraindicated by kidney dysfunction.

High-dose IV iron decreases occurrence of first and recurrent HF events in patients on hemodialysis

Literature - July 12, 2021 - Jhund PS et al. - JACC Heart Fail. 2021

This analysis of the PIVOTAL trial showed that treatment with high-dose IV iron administered proactively, compared to low-dose IV iron administered reactively, decreased the occurrence of first and recurrent HF events in patients receiving hemodialysis.

Phase III trial with SGLT2 inhibitor meets primary endpoint in HFpEF

News - July 6, 2021

EMPEROR-Preserved met its primary endpoint and showed a significant risk reduction with empagliflozin for the composite endpoint of time to first event of CV death or HF hospitalization compared to placebo in adults with HFpEF, with or without T2DM.

No effect of SGLT2i on six minute walk distance in HFrEF and HFpEF

News - July 6, 2021

ESC HF 2021 Dapagliflozin improved HF symptoms (measured by KCCQ-TSS) in HFrEF compared to placebo, but did not improve physical limitations (measured by KCCQ-PLS) or 6 minute walk distance. No significant improvements with dapagliflozin in any of these outcomes were seen in HFpEF.

Clinical effects sGC stimulator in HFrEF after a worsening HF event unaffected by AF status

News - July 5, 2021

ESC HF 2021 This analysis of the VICTORIA trial showed that the beneficial effects of vericiguat were unaffected by AF status at baseline.

Early ARNI treatment initiation after acute decompensated HF well tolerated in HFrEF patients with CKD

News - June 30, 2021

ESC HF 2021 This post hoc analysis of the TRANSITION study demonstrated that early initiation and up-titration of sacubitril/valsartan after acute decompensated HF was well tolerated in HFrEF patients with CKD.

Ferric carboxymaltose improves cardiac function in patients with HFrEF and iron deficiency

News - June 30, 2021

ESC HF 2021 The IRON-CRT trial showed that ferric carboxymaltose improved cardiac function as measured by LVEF, LVESV, and the force-frequency relationship in patients with HFrEF and iron deficiency.

Nonsteroidal MRA reduces CV and kidney outcomes in CKD and T2DM irrespective of HF status

News - June 30, 2021

ESC HF 2021 A subanalysis of FIDELIO-DKD showed that finerenone lowered CV and kidney outcomes compared to placebo in patients with T2DM and CKD irrespective of pre-existing HF status.

Testing rates for iron deficiency in HF are low in real-world population

News - June 29, 2021

ESC HF 2021 In a nation-wide HF registry, screening for iron deficiency was performed in only 27% of patients. 19% Of patients with iron deficiency received treatment with ferric carboxymaltose.

Preview of the 2021 ESC/HFA heart failure guidelines

News - June 29, 2021
Key messages of the 2021 ESC/HFA Guidelines for Heart Failure include a simplified treatment algorithm for HFrEF based on early administration of 4 classes of drugs, including SGLT2i, and tailored-treatment approaches based on phenotypes.

ESC HF 2021 Key messages of the 2021 ESC/HFA Guidelines for Heart Failure include a simplified treatment algorithm for HFrEF based on early administration of 4 classes of drugs, including SGLT2i, and tailored-treatment approaches based on phenotypes.